poisar

Stocks · News reference

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

Benzinga Insights

Dare Bioscience (NASDAQ:DARE) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DARE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose

    The article, titled, "An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults," discusses

    DARE